... $57.52 |EPS 2009 (E): $3.86 | |52 Week Low: $28.62 | | [pic] Executive Summary As analysts we were called upon to enact our due diligence in dealing with the proposed purchase of Eli Lilly common stock. We performed various analyses, which included strategy analysis, fundamental analysis, valuation, and risk assessment. Our absolute valuation calculation shows that Eli Lilly is slightly undervalued however; our relative valuation calculation shows that Eli Lilly is fairly valued. We decided to use the relative valuation recommendation because of the risk that is involved in the industry today. Current risk factors that are threatening Eli Lilly are the FDA approval process, patent expirations, pipeline concerns, the purchase of Imclone and how it will be integrated into the company, and finally the ongoing recession. Eli Lilly currently has drugs pending FDA approval, notably Effient, a...
Words: 8055 - Pages: 33
...Ventures do not always work and when they do they don’t work indefinitely. What Eli Lilly and Ranbaxy are facing now is the dilemma of rather to continue with their JV, Eli Lilly Ranbaxy, or should they separate and continue each one by its own means. The situation represents both a problem and an opportunity to both companies, as there are important trade-offs to be considered before any decision is taken. The Environment In the last decade the environment for the pharmaceutical industry changed radically in India. Before the 1990’s there were no regulations for patent recognition and the government had an active role in establishing drug prices through the DPCO, which were situated amongst the lowest in the world. Profit margins were also regulated at around 6% of sales. As a result many of the multinationals started exiting the Indian market. As India enter the GATT and the WTO in 1994 patent protection would become active in India from 2004-2005. In the international arena, patent regulation was also little by little becoming stronger and many of the big players were going through M&A processes that further increased the sales concentration in few companies. These companies had a hard time competing with local laboratories that produced generic drugs with no R&D expenses and at a fraction of the price. Eli Lilly Ranbaxy portraits the example of the traditional JV in which Ranbaxy, a company from less-industrialized country, offered the knowledge and distribution infrastructure...
Words: 1256 - Pages: 6
...Pfizer (PFE) Financial Analysis for 2012, 2013 and 2014: Ratio Analysis Abstract The following is a list of these ratios, in conjunction with associative details and background to itemize and explicate the overall financial enquiry: Earnings per Share (EPS), which will illustrate current, along with expected, product losses, unfavorable impact and any adverse change in a foreign exchange rate, along with adjustable income attributable to Pfizer and its shareholder's guidance. The next ratio considered would be Profit Margin Ratio, or Net Profit Margin, to characterize the settlement of adjusted income and weakened EPS guidance to reported net income. With the Return on Assets ratio, stakeholders can configure and acquire current, as well as anticipated dividends, all while maintaining sufficient capital to invest successively and increase global shareholder value – which for now, can maintain to support the annual dividend growth, in addition to the accompanied Gross Profit Rate. Together with this, a Return on Common Stockholders’ Equity can be taken into account with regards to commercial and business development opportunities – leading to a direct, shareholder-value enhancement through actual dividends and repurchases. On the other side of the spectrum, Pfizer’s Current and Cash Debt Coverage ratios clarify and expound upon the potential, yet significant, expected adverse events on revenues due to possible loss and expiration of intellectual property and licensing rights...
Words: 1814 - Pages: 8
...Information Services via the World Trade Atlas, U.S. State Export Edition. To receive free copies of the export report please contact the Indiana Economic Development Corporation’s Office of International Trade at 317.232.4949. Direct questions to the authors of the report to Larry Davidson at davidso@indiana.edu or 812.855.2773. Introduction This paper summarizes the results of our global pharmaceutical industry analysis and is intended to increase awareness of the general public – investors, policy makers, managers, employees of the companies – about its current developments. The paper has the following major goals: 1) To analyze the current situation, major challenges and the prospects of the pharmaceutical industry; 2) To identify major players of the global pharmaceutical industry and make a comparative analysis of their business practices and financial results; 3) To determine the relative position of the U.S. pharmaceutical companies in the global pharmaceutical industry, as well as to reveal opportunities for further strengthening of their positions. The paper consists of three major parts. In the first part we present an overview of the pharmaceutical industry as a whole – its major players, current trends and challenges. The second part focuses on a more detailed analysis of major pharmaceutical...
Words: 10094 - Pages: 41
...Information Services via the World Trade Atlas, U.S. State Export Edition. To receive free copies of the export report please contact the Indiana Economic Development Corporation’s Office of International Trade at 317.232.4949. Direct questions to the authors of the report to Larry Davidson at davidso@indiana.edu or 812.855.2773. Introduction This paper summarizes the results of our global pharmaceutical industry analysis and is intended to increase awareness of the general public – investors, policy makers, managers, employees of the companies – about its current developments. The paper has the following major goals: 1) To analyze the current situation, major challenges and the prospects of the pharmaceutical industry; 2) To identify major players of the global pharmaceutical industry and make a comparative analysis of their business practices and financial results; 3) To determine the relative position of the U.S. pharmaceutical companies in the global pharmaceutical industry, as well as to reveal opportunities for further strengthening of their positions. The paper consists of three major parts. In the first part we present an overview of the pharmaceutical industry as a whole – its major players, current trends and challenges. The second part focuses on a more detailed analysis of major pharmaceutical...
Words: 10094 - Pages: 41
...Analysis 18-21 Business-Level Strategy 22-24 Corporate Level Strategy 25-27 Strategy Implementation 28-30 References 31 Executive Summary A Customer’s Hope Eli Lilly and Company is on a mission that benefits millions of people every day by helping them live longer and fuller lives. They provide their customers with answers that matter—life saving and enhancing medicines. They carry out this mission by discovering, developing, and marketing pharmaceutical therapies. Many of the pharmaceutical products Lilly brings to market are first-in-class, providing customers a therapeutic relief that did not exist. An example of this is their newly FDA-cleared drug, Xigris™, which helps thousands of people every day by treating the potentially fatal condition of sepsis. The Lilly research team persevered over two decades to bring Xigris™ to fruition, even when over ten other companies failed to produce a viable drug remedy for sepsis (Eli Lilly Annual Report 2001). This dedication truly exemplifies Lilly’s commitment to their customers and transcends into all their efforts. Eli Lilly continues to be a successful pharmaceutical company, while other pharmaceutical companies have seen their success erode, because of the strategies they employ. Lilly has focused on building partnerships rather than acquisitions and continually reinvests the highest percentage of their sales revenue into research and development. Both of these actions allow them...
Words: 11111 - Pages: 45
...aware that the project will not be accepted unless this form has been handed in along with the project. Signed:_____________________ 2 Table of Contents Introduction – Page:4 External Marketing Audit – Page: The Market – Page: 6-11 Competition – Page: 11 - 14 Internal Marketing Audit – Page: 14 Strategic Issues Analysis – Page: 14 - 21 SWOT Analysis – Page: 21-24 Marketing Objectives – Page: 24 -25 Marketing Mix Decisions – Page: 25 - 29 Organisation and Implementation – Page: 29 -31 Control – Page: 31 -32 Bibliography : 33- 34 4- 6 3 Introduction Through extensive External and Internal analysis, the formulation for the best fit strategy has been developed and refined to suit the resources, culture and infrastructure of Lilly ICOS LLC. The name of the drug has been changed and the marketing approach developed as per the findings of the Macro environment, the Market, Competition, Internal Marketing Audit, and a SWOT Analysis. A decision on each of the marketing mix is taken to compliment the strategy chosen based on the competencies and resources of the product team. There was also a suggested means of...
Words: 11768 - Pages: 48
...Bottom of Form |Read full version essay Case Analysis : Pharma Industry | |Case Analysis : Pharma Industry | |Print version essay is available for you! You can search Free Term Papers and College Essay Examples written by students!. | |Join Essays24.com and get instant access to Case Analysis : Pharma Industry and over 30,000 other Papers and Essays | | | | | |Category: Business | |Autor: anton 06 June 2011 ...
Words: 4303 - Pages: 18
...ABBOTT Laboratories (ABT) Financial Ratio Case Study Company Profile: Abbott Laboratories (ABT) 100 Abbott Park Road Abbott Park, IL 60064-6400 Phone: 847-937-6100 Fax: 847-937-1511 Website: http://www.abbott.com Sector: Healthcare CEO: Miles D. White Number of Employees: 91,000 Major areas of operations: Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Abbott Laboratories (ABT) is an American-based global, diversified pharmaceuticals and health care products company. It employs about 91,000 employees and operates in more than 130 countries around the world. The company headquarters are in Abbott Park, North Chicago, Illinois. The company was founded by Chicago physician, Dr. Wallace Calvin Abbott in 1888. Abbott's core businesses focus is on pharmaceuticals, medical devices and nutritional products, which have been supplemented through several notable acquisitions throughout the years. Its operation is divided into six major divisions: Animal Health, Diabetes Care, Diagnostics, Molecular Analysis (DNA, RNA, proteins at molecular level) and Nutrition along with Vascular Technologies. In 1985, ABT developed the first HIV blood screening test. They also have a broad range of medical devices, diagnostics and immunoassay products as well as nutritional products, including Ensure, a line of well known meal replacement shakes, and EAS, the largest producer of performance based nutritional supplements. ABT’s in vitro...
Words: 2317 - Pages: 10
...and present your portfolio in a professional manner. The initial round of investments to our portfolio was comprised of seven domestic stocks. The main goal was to acquire stable, well-known companies that would pose low risk. These stocks were selected with minimal analysis due to their market capitalizations and the associated company’s reputations. We selected several Blue chip stocks, because they appeared to match our goals of stability and minimizing risk. Since these companies are very large, well established corporations, we understood that the possibility of significant growth in equity is unlikely due to the established maturity of the companies. For this reason, we did not expect to earn our largest return in this area of our portfolio, but instead we were hoping for small growth, while collecting dividends. The first stock purchased was Microsoft (MSFT). Microsoft is a large cap computer software company, listed on the Nasdaq. We purchased 1500 shares at 33.00/share. We still maintain a long position on Microsoft, and the stock is currently trading at 38.45, a 16.52% increase from our original purchase price. Microsoft also paid a dividend of .28/share, totaling 420.00. The second stock purchased was the large cap global insurance company, American International Group Inc....
Words: 3952 - Pages: 16
...business activities and earn revenues and incur expenses. 2. Operating results are regularly reviewed by the chief operating decision-maker to assess performance and make resource allocation decisions. 3. Discrete financial information is available from the internal reporting system. C. Once operating segments have been identified, three quantitative threshold tests are then applied to identify segments of sufficient size to warrant separate disclosure. Any segment meeting even one of these tests is separately reportable. 1. Revenue test—segment revenues, both external and intersegment, are 10 percent or more of the combined revenue, external and intersegment, of all reported operating segments. 2. Profit or loss test—segment profit or loss is 10 percent or more of the greater (in absolute terms) of the combined reported profit of all profitable segments or the combined reported loss of all segments incurring a loss. 3. Asset test—segment assets are 10 percent or more of the combined assets of all operating segments. D. Several general restrictions on the presentation of operating segments exist. 1. Separately reported operating segments must generate at least 75 percent of total sales made by the company to outside parties. 2. Ten is suggested as the maximum number of operating segments that should...
Words: 7852 - Pages: 32
...Perspective Bekaert/Hodrick International Financial Management Berk/DeMarzo Corporate Finance* Berk/DeMarzo Corporate Finance: The Core* Berk/DeMarzo/Harford Fundamentals of Corporate Finance* Boakes Reading and Understanding the Financial Times Brooks Financial Management: Core Concepts* Copeland/Weston/Shastri Financial Theory and Corporate Policy Dorfman/Cather Introduction to Risk Management and Insurance Eiteman/Stonehill/Moffett Multinational Business Finance Fabozzi Bond Markets: Analysis and Strategies Fabozzi/Modigliani Capital Markets: Institutions and Instruments Fabozzi/Modigliani/Jones/Ferri Foundations of Financial Markets and Institutions Finkler Financial Management for Public, Health, and Not-for-Profit Organizations Frasca Personal Finance Gitman/Joehnk/Smart Fundamentals of Investing* Gitman/Zutter Principles of Managerial Finance* * denotes Gitman/Zutter Principles of Managerial Finance— Brief Edition* Goldsmith Consumer Economics: Issues and Behaviors Haugen The Inefficient Stock Market: What Pays Off and Why Haugen The New Finance: Overreaction, Complexity, and Uniqueness Holden Excel Modeling and Estimation in Corporate Finance Holden Excel Modeling and Estimation in Investments Hughes/MacDonald International Banking: Text and Cases Hull Fundamentals of Futures and Options Markets Hull Options, Futures, and Other Derivatives Hull Risk Management and Financial Institutions McDonald Fundamentals...
Words: 4858 - Pages: 20
...Perspective Bekaert/Hodrick International Financial Management Berk/DeMarzo Corporate Finance* Berk/DeMarzo Corporate Finance: The Core* Berk/DeMarzo/Harford Fundamentals of Corporate Finance* Boakes Reading and Understanding the Financial Times Brooks Financial Management: Core Concepts* Copeland/Weston/Shastri Financial Theory and Corporate Policy Dorfman/Cather Introduction to Risk Management and Insurance Eiteman/Stonehill/Moffett Multinational Business Finance Fabozzi Bond Markets: Analysis and Strategies Fabozzi/Modigliani Capital Markets: Institutions and Instruments Fabozzi/Modigliani/Jones/Ferri Foundations of Financial Markets and Institutions Finkler Financial Management for Public, Health, and Not-for-Profit Organizations Frasca Personal Finance Gitman/Joehnk/Smart Fundamentals of Investing* Gitman/Zutter Principles of Managerial Finance* * denotes Gitman/Zutter Principles of Managerial Finance— Brief Edition* Goldsmith Consumer Economics: Issues and Behaviors Haugen The Inefficient Stock Market: What Pays Off and Why Haugen The New Finance: Overreaction, Complexity, and Uniqueness Holden Excel Modeling and Estimation in Corporate Finance Holden Excel Modeling and Estimation in Investments Hughes/MacDonald International Banking: Text and Cases Hull Fundamentals of Futures and Options Markets Hull Options, Futures, and Other Derivatives Hull Risk Management and Financial Institutions McDonald Fundamentals...
Words: 4858 - Pages: 20
...OUTPERFORM NOVARTIS Switzerland – Market price at 11/30/2015 closing price: $90.43 DEVAUX Paul, MÉAR Germain – 11/03/2015 Activities: Novartis is the number one pharmaceutical company in the world regarding sales: $47,101 million in 2014. Its headquarters are in Basel, in Switzerland. This company was born from the merger of Ciba-Geigy and Sandoz in 1996. Those companies are both Swiss company with a great history in this sector. The merger of J.R GEIGY LTD and CIBA also formed Ciba-Geigy. Those both companies were founded in Basel In 1758 and 1859. Novartis famous drugs are: • Clozapine (Clozaril) used in the treatment of schizophrenia • Diclofenac (Voltaren) used to reduce inflammation • Pharmaceutical Industry Sector Extreme (52w)) Lowest $88.89 Highest $107.1 Latest price $91.04 Vaksartan (Diovan) used to treat high blood pressure Novartis focused first on its pharmaceutical and agrochemical activities and sold other businesses. Novartis is operating directly and through dozens of subsidiaries in countries around the world. There are three key divisions in Novartis: Pharmaceuticals, Alcon and Sandoz. Its pharmaceuticals division aims at providing innovative and important medicines for health needs. It has a portfolio of over sixty medicines, which often are leaders in their therapeutic areas. In addition, this division is currently working on more than...
Words: 3850 - Pages: 16
...EnviroTech. Such a solution can be found with the right implementation of the HR domain statement, nine step problem solving process, effective change management and conscientious decision making. The paper tries to identify the various issues related to the merger, challenges, opportunities, solution paths, time lines and risks associated with the implementation of solutions. The paper also provides a set of timelines and metrics for measurement of the outcomes. Situation Analysis Issue and Opportunity Identification InterClean belongs to an eight billion dollar industrial cleaning and sanitation industry. As per the scenario, the principal stakeholders are trying to increase the profitability of the company through change in the business strategy and by the acquisition of a new company EnviroTech, an acquisition that is in-line with new business strategy and bound to achieve the targeted profitability of 40%.(University of Phoenix, 2008). Based on the decisions of David (President and CEO), the HR have taken immediate steps at performing skill gap analysis and identifying the best strategy for staffing the organization. This knee jerk reaction has created lot of confusion amongst the sales staff, with no direct or indirect form of communication establishing the cause-effect relationships leading to creation of an environment fostering disengagement. The opportunity however, is for formalization of the business strategy along with the development of a clear...
Words: 4226 - Pages: 17
